About Dezhan Healthcare
Dezhan Healthcare (000813.SZ) specializes in cardio-cerebral vascular drugs, anti-cancer tumor drugs, health care products, functional drinks, ecological water, and others.
Dezhan Healthcare Headquarter Location
10/F, Meilin Building 2 Gongti East Yi Rd, Chaoyang District
Beijing, Beijing, 100027,
Latest Dezhan Healthcare News
Mar 11, 2019
Dezhan Healthcare to Buy Into China's Biggest Hemp Producer Tang Shihua Dezhan Healthcare to Buy Into China's Biggest Hemp Producer (Yicai Global) March 11 -- Chinese generic drug developer Dezhan Healthcare plans to buy into the country's largest industrial hemp operator Hanma Investment Group as Chinese investors lavish more attention on companies that break into this budding sector. The Beijing-headquartered company has penned a six-month exclusive strategic cooperation framework agreement with HMI Group's shareholder Hanzhong Group and HMI Group itself, per a recent announcement from Dezhan Healthcare. The firm has developed a cannabidioid medication -- used to treat a host of disorders from anxiety to inflammation –- and is exploring cooperation with Las Vegas, Nevada-based Cannamaster to market it in the US, the firm announced on its website. This move follows the US Food and Drug Administration's approval of a CBD medication to treat seizures in June. The parties will investigate and research and consult with each other during their six-month exclusive cooperation, per the announcement, which states the direct share purchase, set up of a joint venture, investment in the target company through an investment fund, transfer of patents and proprietary technologies and joint research and development are among the various possible forms of subsequent cooperation. Dezhan Healthcare will pay Hanzhong Group CNY400 million (USD60 million) as earnest money to signify its sincere desire for cooperation, with the latter transferring 25 percent of its shares in the target to HMI Group as a pledge, per the announcement. The two must complete all procedures to dissolve the equity pledge within six days if they fail extend the framework agreement after it expires. Medicine, food, healthcare, agricultural planting and feed are the major applications in which hemp, which is cannabis that contains less than 0.3 percent of the psychoactive ingredient Tetrahydrocannabinol, find use. China boasts more than half of the world's cultivated area of the fibrous plant -- which is a relative of hops and nettles -- and holds multiple technical patents for its commercial application. The cultivation and processing of hemp has until lately been a relatively unpopular sector in China, and the HMI Group, which has not yet listed, is the major industry operator in the country. Canadian embassy officials representing the western hemp-growing province of Alberta recently met in Beijing with company Board Chairman Tax Xin to discuss cooperation, the company reported on its website. Shares of various listed companies have steadily increased since the start of 2019 as these announced that they would invest in areas including the cultivation and product research and development of industrial hemp and/or received grant of hemp-cultivation permits, drawing the hungry gaze of all kinds of capital. Shares of Shanghai-based Shunho New Materials Technology [SHE:002565] hit the limit up of 10 percent on Jan. 17 bourse rules impose after its wholly-owned unit Yunnan Luxin Biological Pharmaceutical secured an industrial hemp planting license from Yunnan province in southwestern China, Yicai Global reported, as did Conba Pharmaceutical's stock [SHA:600572] on Feb. 21 after the Chinese drugmaker won approval to start planting industrial hemp. Marijuana stocks may be taking off in countries and regions that have legalized recreational use of its more psychedelic sister, but in China homely old Hemp is still queen and quite likely an even more solid -- if more stolid -- investment opportunity. Editor: Ben Armour